GET DAILY SIGNALSPRFX: PRF Technologies Ltd.'s Move Toward a Broader Innovation Platform
Key Takeaways
- PRFX is the Nasdaq ticker for PRF Technologies Ltd., formerly known as PainReform Ltd., a clinical-stage company that changed its name in January 2026 to reflect a broader strategy.
- The company operates across two main areas: specialty pharmaceuticals and drug-delivery technologies, alongside AI-driven renewable-energy analytics.
- Its lead pharmaceutical candidate, PRF-110, is a non-opioid, extended-release local anesthetic targeting postoperative pain relief.
- Through subsidiaries and business units such as LayerBio (ophthalmology) and DeepSolar (AI-driven solar analytics), the company has diversified beyond a single-product focus.
- As a clinical-stage and early-commercialization company, PRF Technologies carries significant development, regulatory, and financial risks.
Company Snapshot
PRFX represents the stock of PRF Technologies Ltd., a small-cap Israeli company listed on the Nasdaq. The firm develops reformulated and sustained-release drug-delivery technologies and is also building an AI-driven renewable-energy analytics platform. I follow PRFX mainly for its lead pain-management candidate and its recent efforts to expand into ophthalmology and clean-energy technology, which have helped spread its long-term positioning beyond one pharmaceutical asset.
Business Evolution and Profile
PRF Technologies Ltd. was incorporated in Israel in November 2007 and started trading on the Nasdaq in September 2020. Its main offices are in Tel Aviv. For years the company operated as PainReform Ltd., a specialty pharmaceutical business centered on reformulating existing therapeutics. In January 2026, shareholders approved the name change to PRF Technologies Ltd. to better capture its growth into a diversified platform that includes specialty pharmaceuticals, drug-delivery technologies, and AI-driven renewable-energy analytics.
Historically, the core focus has been PRF-110, an oil-based, viscous solution using the local anesthetic ropivacaine. PRF-110 is meant to be placed directly into a surgical wound for localized, extended postoperative pain relief without opioids or NSAIDs. The business model centers on moving this candidate through clinical development toward commercialization as a pain-management option for surgical patients. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Over time, PRF Technologies has added new segments. Its majority-owned subsidiary LayerBio brought the company into ophthalmology with OcuRing-K, a sustained-release, bio-erodible implant for managing pain and inflammation after cataract surgery and potentially reducing the need for post-surgical eye drops. The DeepSolar unit develops AI-based analytics for utility-scale solar and energy-storage assets, including forecasting and revenue-optimization tools.
As a clinical-stage and early-commercialization company, PRF Technologies still generates minimal revenue and has reported operating losses, which is typical for development-stage pharmaceutical firms. Future revenue would come from commercializing product candidates and growing the energy-analytics platform. The company competes in crowded spaces: postoperative pain management includes established extended-release anesthetics and generics, while solar analytics features various established software providers.
Why Investors Track PRFX
Attention around PRFX stems from several longer-term themes. The lead candidate PRF-110 targets the sizable postoperative pain market, where a non-opioid, extended-release option could help address opioid concerns and offer a differentiated profile. Diversification into ophthalmology through LayerBio and OcuRing-K spreads the pharmaceutical pipeline beyond one asset, which may lower concentration risk over time.
The AI-driven energy business, DeepSolar, also gives PRF Technologies exposure to the expanding renewable-energy data and analytics segment, an area drawing more interest as solar and battery-storage assets grow. For investors, PRFX offers a speculative, development-stage opportunity with exposure to both healthcare innovation and clean-energy technology trends. Its small market capitalization and early stage mean valuation is driven mainly by clinical milestones, partnerships, and platform progress rather than current earnings.
Risks and Key Considerations
Investing in PRFX carries substantial risks. As a clinical-stage company, PRF Technologies relies heavily on the success of a limited number of candidates, especially PRF-110 and OcuRing-K. Drug development is lengthy and costly, with no assurance of regulatory approval or commercial success. Intense competition from larger pharmaceutical companies with deeper resources and established networks adds pressure.
Financial risk remains notable. The company has generated little revenue and reported net losses, which may lead to further capital raises that could dilute shareholders. The shift into renewable-energy analytics and AI introduces execution risk in newer areas of the business. Macroeconomic factors, regulatory hurdles in both pharmaceuticals and energy, and small-cap volatility are other elements to weigh.
Using AI Tools in My Research
When screening for ideas across sectors, I often rely on Tickeron’s AI Screener. This platform lets me apply technical indicators, fundamentals, volatility measures, trends, AI-generated signals, industry filters, and price patterns to scan thousands of stocks and ETFs quickly. It helps surface candidates that align with specific strategies and supports building watchlists without manual effort on every name.
Conclusion
PRF Technologies Ltd. is a small-cap, development-stage company that has evolved from a single-product pain-reformulation focus into a diversified platform covering specialty pharmaceuticals, ophthalmology drug delivery, and AI-driven renewable-energy analytics. This broader scope sets it apart among early-stage issuers, yet it also brings added complexity and execution risk. PRFX remains a speculative way to gain exposure to innovation in healthcare and clean-energy technology, best viewed as a high-risk, early-stage narrative driven by clinical milestones and platform development rather than current profitability.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for PRFX turns positive, indicating new upward trend
PRFX saw its Momentum Indicator move above the 0 level on November 04, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 99 similar instances where the indicator turned positive. In 89 of the 99 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where PRFX's RSI Indicator exited the oversold zone, 46 of 52 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Moving Average Convergence Divergence (MACD) for PRFX just turned positive on October 28, 2026. Looking at past instances where PRFX's MACD turned positive, the stock continued to rise in 42 of 52 cases over the following month. The odds of a continued upward trend are 81%.
Following a +8.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where PRFX advanced for three days, in 154 of 186 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PRFX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
PRFX broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for PRFX entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 35 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.192) is normal, around the industry mean (7.254). P/E Ratio (-0.213) is within average values for comparable stocks, (0.575). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.061) among similar stocks. P/S Ratio (34.722) is also within normal values, averaging (181.047).
The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. PRFX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PRFX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PharmaceuticalsGeneric
Advertisement